PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
6289276-2	1982	Notably, in humans, intravenous infusion of centrally active cholinomimetic drugs, such as physostigmine or arecoline, may produce significant increases in plasma concentrations of prolactin and beta-endorphin immunoreactivity.	Arecoline	108-117	proopiomelanocortin	Homo sapiens	195-209	
1659617-3	1991	The mechanisms underlying diminished plasma corticotropin (ACTH) responses to arecoline may differ in patients with autonomic failure.	Arecoline	78-87	proopiomelanocortin	Homo sapiens	59-63	
6289276-3	1982	In three separate studies, conducted collaboratively between the National Institute of Mental Health and the University of California at San Diego, physostigmine and arecoline associated increases in plasma concentrations of beta-endorphin immunoreactivity were highly correlated with increases in plasma prolactin concentrations.	Arecoline	166-175	proopiomelanocortin	Homo sapiens	225-239	
8584603-8	1995	Acute arecoline administered to 14 subjects produced unpleasant side-effects (e.g. nausea, vomiting), mean adrenocorticotrophic hormone (p = .0006), cortisol (p = .0001) and beta-endorphin (p = .0001) levels were elevated.	Arecoline	6-15	proopiomelanocortin	Homo sapiens	174-188	
7797620-3	1995	We investigated the effect of a muscarinic cholinergic agonist, arecoline, which stimulates the secretion of corticotropin-releasing hormone (CRF) and adrenocorticotropic hormone (ACTH) on the immune system.	Arecoline	64-73	proopiomelanocortin	Homo sapiens	151-178	
7797620-3	1995	We investigated the effect of a muscarinic cholinergic agonist, arecoline, which stimulates the secretion of corticotropin-releasing hormone (CRF) and adrenocorticotropic hormone (ACTH) on the immune system.	Arecoline	64-73	proopiomelanocortin	Homo sapiens	180-184